Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology

In: International Journal of Immunology · 2020 · vol. 8(1) , pp. 1 · doi:10.11648/j.iji.20200801.11 · W3009534707
article OA: diamond CC0 ⤵ 3 in-corpus citations
📄 Open PDF View on OpenAlex View at publisher

Abstract

The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (3)

References (12)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK